An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd et al. · Journal of Clinical Oncology · 1999 · 943 citations

BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo

Martin Steegmaier, Matthias Hoffmann, Anke Baum et al. · Current Biology · 2007 · 839 citations · Full text

Tumor Biology, Bi 2536, Medicine +9

The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

Edmund A. Gehan · Journal of Chronic Diseases · 1961 · 668 citations

Medicine, Clinical Endpoint, Clinical Trials +7

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

Mary O’Brien, Tudor–Eliade Ciuleanu, H. Tsekov et al. · Journal of Clinical Oncology · 2006 · 628 citations · Full text

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

Xiaoqi Liu, Raymond L. Erikson · Proceedings of the National Academy of Sciences · 2003 · 468 citations · Full text

Tumor Biology, Chromatin, Chromatin Structure +14